Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2-i in Obesity Associated Cardiomyopathy
NCT05764811Completed
- Sponsor
- National Cheng Kung University Hospital
- Start
- Mar 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of canagliflozin in fatty liver disease (FLD) and cardiomyopathy (2 arms), sponsored by National Cheng Kung University Hospital. Primary endpoint: Severity of fatty liver via MRI at 4 weeks. Started Mar 2020; status: completed.
02
Drugs
canagliflozin
03
Conditions
fatty liver disease (FLD)cardiomyopathy
Beyond the preview
Go deeper on NCT05764811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05764811.